BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

949 related articles for article (PubMed ID: 17644532)

  • 1. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.
    Peralta G; Sánchez MB; Garrido JC; De Benito I; Cano ME; Martínez-Martínez L; Roiz MP
    J Antimicrob Chemother; 2007 Oct; 60(4):855-63. PubMed ID: 17644532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
    Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
    J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of healthcare-associated infections in community-onset Escherichia coli bacteraemia.
    Cheong HS; Kang CI; Kwon KT; Heo ST; Wi YM; Kim ES; Lee JS; Ko KS; Chung DR; Lee NY; Song JH; Peck KR
    J Antimicrob Chemother; 2007 Dec; 60(6):1355-60. PubMed ID: 17923453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy.
    Lautenbach E; Metlay JP; Bilker WB; Edelstein PH; Fishman NO
    Clin Infect Dis; 2005 Oct; 41(7):923-9. PubMed ID: 16142655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comment on: Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia.
    Blot S; Vandijck D; Vandewoude K; Depuydt P; Vogelaers D; Peleman R
    J Antimicrob Chemother; 2007 Dec; 60(6):1402. PubMed ID: 17913718
    [No Abstract]   [Full Text] [Related]  

  • 6. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome.
    Gudiol C; Calatayud L; Garcia-Vidal C; Lora-Tamayo J; Cisnal M; Duarte R; Arnan M; Marin M; Carratalà J; Gudiol F
    J Antimicrob Chemother; 2010 Feb; 65(2):333-41. PubMed ID: 19959544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
    Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
    J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
    Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
    J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piperacillin-resistant Escherichia coli bacteraemia: relation to empiric therapy and clinical outcome.
    Andersen NF; Møller J; Peterslund NA
    Scand J Infect Dis; 2005; 37(2):90-5. PubMed ID: 15764199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity and smoking are factors associated with poor prognosis in patients with bacteraemia.
    Huttunen R; Laine J; Lumio J; Vuento R; Syrjänen J
    BMC Infect Dis; 2007 Mar; 7():13. PubMed ID: 17349033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
    Arslan H; Azap OK; Ergönül O; Timurkaynak F;
    J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region.
    Laupland KB; Gregson DB; Church DL; Ross T; Pitout JD
    Clin Microbiol Infect; 2008 Nov; 14(11):1041-7. PubMed ID: 19040476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-to-positivity in patients with Escherichia coli bacteraemia.
    Peralta G; Roiz MP; Sánchez MB; Garrido JC; Ceballos B; Rodríguez-Lera MJ; Mateos F; De Benito I
    Clin Microbiol Infect; 2007 Nov; 13(11):1077-82. PubMed ID: 17727685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia.
    Metan G; Sariguzel F; Sumerkan B
    Eur J Intern Med; 2009 Sep; 20(5):540-4. PubMed ID: 19712862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjustment of antibiotic treatment according to the results of blood cultures leads to decreased antibiotic use and costs.
    Berild D; Mohseni A; Diep LM; Jensenius M; Ringertz SH
    J Antimicrob Chemother; 2006 Feb; 57(2):326-30. PubMed ID: 16387751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia.
    Van Aken S; Lund N; Ahl J; Odenholt I; Tham J
    Scand J Infect Dis; 2014 Nov; 46(11):753-62. PubMed ID: 25195648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical consequences of increased ciprofloxacin and gentamicin resistance in patients with Escherichia coli bacteraemia in the Netherlands.
    Cranendonk DR; van der Valk M; Langenberg ML; van der Meer JT
    Scand J Infect Dis; 2012 May; 44(5):363-8. PubMed ID: 22200089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple-drug-resistant bacteria in patients with severe acute exacerbation of chronic obstructive pulmonary disease: Prevalence, risk factors, and outcome.
    Nseir S; Di Pompeo C; Cavestri B; Jozefowicz E; Nyunga M; Soubrier S; Roussel-Delvallez M; Saulnier F; Mathieu D; Durocher A
    Crit Care Med; 2006 Dec; 34(12):2959-66. PubMed ID: 17012911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies.
    Trecarichi EM; Tumbarello M; Spanu T; Caira M; Fianchi L; Chiusolo P; Fadda G; Leone G; Cauda R; Pagano L
    J Infect; 2009 Apr; 58(4):299-307. PubMed ID: 19272650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.